Korea Market Entry Checklist for Foreign Medical Device Manufacturers

Phase 0: Market Opportunity Assessment

Before any regulatory work:

Market Sizing

Confirm Korean market size for your device category (KMDIA / IQVIA Korea reports)
Identify top 5 competitors already approved in Korea
Map Korean hospital/clinic adoption patterns
Assess HIRA reimbursement status of comparable devices
Validate distributor or direct-sales business model

Strategic Fit

Confirm Korea fits multi-year market strategy (not opportunistic)
Allocate $50K–$200K initial regulatory budget
Identify Korean-fluent staff or external partners
Confirm CE Mark or FDA 510(k) status (accelerates Korean pathway)

Phase 1: Regulatory Pathway Decision

Device Classification

Determine MFDS Class (I, II, III, or IV) per Korean Medical Device Classification Code
Cross-check with FDA and EU MDR classifications (often differ)
Identify any borderline classification risks
If unclear: engage MFDS pre-submission consultation

Pathway Selection

Class	Pathway	Decision
Class I	Notification (신고)	Fast path, KGMP not required
Class II	Registration (허가)	Standard path, KGMP required
Class III	Registration (허가)	Clinical evidence required
Class IV	Registration (허가)	Highest scrutiny, clinical study likely

Clinical Evidence Path

Inventory existing clinical data (FDA pivotal, EU CER, real-world evidence)
Identify MFDS-approved equivalent devices (for equivalence-based evidence)
Determine if Korean clinical study required
Plan clinical evidence preparation timeline (4 weeks to 24+ months)

Phase 2: Korea License Holder (KLH) Strategy

KLH Options

Decide between distributor-as-KLH vs independent KLH
If multiple distributors planned: independent KLH strongly preferred
If single long-term distributor: distributor-as-KLH acceptable with proper agreement
Engage Korean legal counsel for KLH agreement review

KLH Setup Tasks

Execute KLH services agreement
Verify KLH Korean business registration (사업자등록)
Confirm KLH vigilance reporting capacity
Establish MFDS correspondence routing (KLH → manufacturer)

Phase 3: KGMP Preparation (Class II+)

Gap Analysis

Map existing ISO 13485 QMS against KGMP requirements
Identify Korea-specific gaps (design history file, change control, supplier audits)
Build remediation plan (typical 6–12 weeks)
Translate critical SOPs to Korean

Inspection Preparation

Schedule MFDS KGMP inspection (3–6 months lead time)
Conduct internal mock audit
Prepare Korean translations of inspection-critical records
Train staff on MFDS inspector expectations

Cost Planning

Budget $11K–$30K KGMP inspection fees + travel
Plan 4–6 month KGMP timeline running parallel to product registration

Phase 4: Documentation Preparation

Korean STED Preparation

Audit existing CE Mark or FDA 510(k) technical files
Build STED in 8-section MFDS structure (6–8 weeks)
Adapt clinical evaluation for Korean context
Draft Korean labeling and IFU (MFDS Notice 2022-110 compliant)
Internal QA review against common deficiency patterns

Translation Strategy

Identify Korean regulatory writer (not generic translation)
Reserve sections for native Korean drafting (Risk Management, Labeling, IFU)
Plan 2–3 rounds of regulatory translation review

Phase 5: Submission and Approval

Pre-Submission

MFDS pre-submission consultation (optional, recommended for novel devices)
Final internal review against MFDS submission checklist
KLH coordination for filing logistics
Backup documentation ready for deficiency responses

Submission

File through MFDS electronic portal via KLH
Pay MFDS official fees (Class I: ~$220; Class II: $3K–$6K; Class III–IV: $9K–$15K)
Confirm submission acceptance (filing number issuance)

Review Period

Class I: 30–60 days
Class II: 60–90 days
Class III–IV: 6–12 months
Plan deficiency response capacity (5–15 days typical response window)

KMD Number Issuance

Receive MFDS Product License (KMD number)
Update Korean labels with KMD number
Confirm KLH ready for post-market obligations

Phase 6: Post-Market Setup

Vigilance and Adverse Events

Establish MFDS adverse event reporting workflow
5-day reporting for fatalities
15-day reporting for serious adverse events
30-day reporting for other reportable events
Korean customer complaint intake process

Change Management

Establish change notification workflow
Maintain change log per Korean Medical Device Law
Plan annual change notification reviews

License Maintenance

Calendar 3-year renewal date
Annual KGMP surveillance audit preparation
Korean labeling updates as needed

Reimbursement (HIRA)

Determine if HIRA listing required for hospital adoption
Plan HIRA submission strategy
Engage Korean health economics analysis (if needed)
HIRA listing typical timeline: 6–18 months post-MFDS

Critical Timeline Overview

Phase	Duration	Cumulative
Phase 0: Market assessment	4–8 weeks	1–2 months
Phase 1: Pathway decision	2–4 weeks	2–3 months
Phase 2: KLH setup	2–4 weeks	2–4 months
Phase 3: KGMP (parallel from Phase 2)	16–24 weeks	4–6 months
Phase 4: Documentation	8–12 weeks	4–6 months
Phase 5: MFDS review	8–24 weeks	6–12 months
Phase 6: Post-market setup	4–8 weeks	7–13 months

Realistic end-to-end: 6–12 months for Class II; 9–18 months for Class III–IV.

Budget Planning Template

Cost Category	Class I	Class II	Class III/IV
Regulatory consulting	$5K–$15K	$25K–$60K	$60K–$150K
MFDS official fees	$220–$1K	$3K–$8K	$9K–$20K
KGMP inspection	N/A	$15K–$30K	$15K–$30K
KLH setup + first year	$10K–$30K	$10K–$30K	$10K–$30K
Translation	$2K–$5K	$5K–$15K	$10K–$25K
Clinical evidence	N/A	$5K–$20K	$50K–$500K+
Total (year 1)	$17K–$50K	$60K–$160K	$150K–$750K+
Annual maintenance (year 2+)	$15K–$30K	$20K–$40K	$25K–$60K

Frequently Asked Questions

Q: What's the most common entry mistake?

A: Submitting before KGMP is scheduled. Without KGMP in hand, MFDS issues conditional approval that delays market entry by 4–6 months.

Q: Can we sell in Korea before MFDS approval?

A: No. Importing or selling non-approved medical devices in Korea is illegal and subject to fines and import bans.

Q: How long does Leanabl typically engage for full market entry?

A: 6–9 months for Class II programs; 9–18 months for Class III. Engagement extends through post-market setup phase.

Q: Do we need a Korean entity?

A: No. The Korea License Holder (KLH) is your Korean entity for regulatory purposes. You can operate as a foreign manufacturer with KLH as your Korean regulatory representative.

Q: How do we handle Korean distribution after approval?

A: Multiple options: appoint single or multiple distributors, direct sales to hospitals (limited), or hybrid models. KLH role is independent of distribution choice.

How Leanabl Helps

Korea Total Access Program — fixed-fee end-to-end entry
Korea Full Market Authorization — MFDS + KGMP + HIRA coordinated
Regulatory Pathway Strategy — initial strategy
KLH Service — independent KLH

Contact Leanabl for a Korea entry strategy session.

Last updated: 2026-05-15.